Multi-omics integration in deciphering non-small cell lung cancer drug resistance: current status, challenges, and future prospects.

IF 2.6 3区生物学

Hereditas Pub Date : 2026-02-02 DOI:10.1186/s41065-025-00570-w

Jidong Miao, Wenqiang Guan, Jing Wang, Huiying Gong, Qian Xie, Yang Gao

{"title":"Multi-omics integration in deciphering non-small cell lung cancer drug resistance: current status, challenges, and future prospects.","authors":"Jidong Miao, Wenqiang Guan, Jing Wang, Huiying Gong, Qian Xie, Yang Gao","doi":"10.1186/s41065-025-00570-w","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer is the leading cause of cancer-related deaths globally. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, and drug resistance severely undermines treatment efficacy. This review summarizes recent advances in elucidating NSCLC drug-resistance mechanisms using multi-omics integration. Multi-omics integration systematically reveals the molecular networks of drug resistance, identifies key biomarkers and targets, and facilitates the screening of high-priority candidates for drug development through experimental validation. Small-molecule inhibitors targeting drug-resistant proteins and multi-omics-guided combination therapies offer strategies to reverse resistance. Future directions involve developing simultaneous multi-omics detection technologies, leveraging artificial intelligence for intelligent data analysis, establishing standardized frameworks for data sharing, and implementing personalized medicine based on multi-omics to improve patient prognosis.</p>","PeriodicalId":12862,"journal":{"name":"Hereditas","volume":"163 1","pages":"5"},"PeriodicalIF":2.6000,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12862923/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hereditas","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s41065-025-00570-w","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Lung cancer is the leading cause of cancer-related deaths globally. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, and drug resistance severely undermines treatment efficacy. This review summarizes recent advances in elucidating NSCLC drug-resistance mechanisms using multi-omics integration. Multi-omics integration systematically reveals the molecular networks of drug resistance, identifies key biomarkers and targets, and facilitates the screening of high-priority candidates for drug development through experimental validation. Small-molecule inhibitors targeting drug-resistant proteins and multi-omics-guided combination therapies offer strategies to reverse resistance. Future directions involve developing simultaneous multi-omics detection technologies, leveraging artificial intelligence for intelligent data analysis, establishing standardized frameworks for data sharing, and implementing personalized medicine based on multi-omics to improve patient prognosis.

查看原文本刊更多论文

多组学整合非小细胞肺癌耐药：现状、挑战和未来展望

肺癌是全球癌症相关死亡的主要原因。非小细胞肺癌（NSCLC）约占所有肺癌病例的85%，耐药严重影响治疗效果。本文综述了利用多组学整合研究非小细胞肺癌耐药机制的最新进展。多组学集成系统地揭示了耐药的分子网络，确定了关键的生物标志物和靶点，并通过实验验证促进了药物开发高优先级候选药物的筛选。靶向耐药蛋白的小分子抑制剂和多组学指导的联合治疗提供了逆转耐药的策略。未来的发展方向包括发展同步多组学检测技术，利用人工智能进行智能数据分析，建立标准化的数据共享框架，以及实施基于多组学的个性化医疗，以改善患者预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hereditas Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

3.80

自引率

3.70%

发文量

期刊介绍： For almost a century, Hereditas has published original cutting-edge research and reviews. As the Official journal of the Mendelian Society of Lund, the journal welcomes research from across all areas of genetics and genomics. Topics of interest include human and medical genetics, animal and plant genetics, microbial genetics, agriculture and bioinformatics.